NCT01623557View on ClinicalTrials.gov

A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

ChAd63-MVA CS

1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.

BIOLOGICAL

ChAd63-MVA ME-TRAP

1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.

OTHER

Controlled Human Malaria Infection Administered by Mosquito Bite

Approximately 3 weeks post MVA dosing

Trial Locations (3)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

SW7 2AZ

Infection and Immunity Section, Imperial College of Science, Technology and Medicine, London

SO16 6YD

Wellcome Trust CRF, Southampton General Hospital, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01623557 - A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates | Biotech Hunter | Biotech Hunter